tbuckley/cabot-search huggingface dataset:
Why treat cirrhosis?
Journal: BMJ (1981)

given into the care of a responsible adult with a warning of their dangers.Any measures which help reduce adult parasuicidal behaviour are likely to help children too.Parental distress is still the cause of most child psychiatric disorder.Child psychiatrists must work more closely with their colleagues in adult psy- chiatry and paediatrics in order to identify and treat parasuicidal children and their parents.
Prediction of Progression in Barrett’s Esophagus Using a Tissue Systems Pathology Test: A Pooled Analysis of International Multicenter Studies
Authors: Prasad G. Iyer, D. Chamil Codipilly, Apoorva K. Chandar, Siddharth Agarwal, Kenneth K. Wang, Cadman L. Leggett, Laureano Rangel Latuche, Phillip J. Schulte
Journal: Clinical Gastroenterology and Hepatology (2022)

Prediction of progression risk in Barrett's esophagus (BE) may enable personalized management. We aimed to assess the adjunct value of a tissue systems pathology test (TissueCypher) performed on paraffin-embedded biopsy tissue, when added to expert pathology review in predicting incident progression, pooling individual patient-level data from multiple international studies METHODS: Demographics, clinical features, the TissueCypher risk class/score, and progression status were analyzed. Conditional logistical regression analysis was used to develop multivariable models predicting incident progression with and without the TissueCypher risk class (low, intermediate, high). Concordance (c-) statistics were calculated and compared with likelihood ratio tests to assess predictive ability of models. A risk prediction calculator integrating clinical variables and TissueCypher risk class was also developed.
Intestinal microbiota signatures of clinical response and immune-related adverse events in melanoma patients treated with anti-PD-1
Authors: John A. McCulloch, Diwakar Davar, Richard R. Rodrigues, Jonathan H. Badger, Jennifer R. Fang, Alicia M. Cole, Ascharya K. Balaji, Marie Vetizou, Stephanie M. Prescott, Miriam R. Fernandes, Raquel G. F. Costa, Wuxing Yuan, Rosalba Salcedo, Erol Bahadiroglu, Soumen Roy, Richelle N. DeBlasio, Robert M. Morrison, Joe-Marc Chauvin, Quanquan Ding, Bochra Zidi, Ava Lowin, Saranya Chakka, Wentao Gao, Ornella Pagliano, Scarlett J. Ernst, Amy Rose, Nolan K. Newman, Andrey Morgun, Hassane M. Zarour, Giorgio Trinchieri, Amiran K. Dzutsev
Journal: Nature Medicine (2022)
BUDAPEST
Journal: JAMA (1921)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Assessing Unexpected Circumstances That Lead to Modifications in Clinical Trial Design, Conduct, or Analysis
Authors: Maria Mori Brooks, Stephen R. Wisniewski
Journal: JAMA (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
SELECTIONS.
Journal: JAMA (1898)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Variation Across Hospitals in In-Hospital Cardiac Arrest Incidence Among Medicare Beneficiaries
Authors: Tyler P. Rasmussen, Danielle J. Riley, Mary Vaughan Sarazin, Paul S. Chan, Saket Girotra
Journal: JAMA Network Open (2022)

<h3>Importance</h3> Although survival for in-hospital cardiac arrest (IHCA) has improved substantially over the last 2 decades, survival rates have plateaued in recent years. A better understanding of hospital differences in IHCA incidence may provide important insights regarding best practices for prevention of IHCA. <h3>Objective</h3> To determine the incidence of IHCA among Medicare beneficiaries, and evaluate hospital variation in incidence of IHCA. <h3>Design, Setting, and Participants</h3> This observational cohort study analyzes 2014 to 2017 data from 170 hospitals participating in the Get With The Guidelines-Resuscitation registry, linked to Medicare files. Participants were adults aged 65 years and older. Statistical analysis was performed from January to December 2021. <h3>Exposures</h3> Case-mix index, teaching status, and nurse-staffing. <h3>Main Outcomes and Measures</h3> Hospital incidence of IHCA among Medicare beneficiaries was estimated as the number of IHCA patients divided by the total number of hospital admissions. Multivariable hierarchical regression models were used to calculate hospital incidence rates adjusted for differences in patient case-mix and evaluate the association of hospital variables with IHCA incidence. <h3>Results</h3> Among a total of 4.5 million admissions at 170 hospitals, 38 630 patients experienced an IHCA during 2014 to 2017. Among the 38 630 patients with IHCAs, 7571 (19.6%) were non-Hispanic Black, 26 715 (69.2%) were non-Hispanic White, and 16 732 (43.3%) were female; the mean (SD) age at admission was 76.3 (7.8) years. The median risk-adjusted IHCA incidence was 8.5 per 1000 admissions (95% CI, 8.2-9.0 per 1000 admissions). After adjusting for differences in case-mix index, IHCA incidence varied markedly across hospitals ranging from 2.4 per 1000 admissions to 25.5 per 1000 admissions (IQR, 6.6-11.4; median odds ratio, 1.51 [95% CI, 1.44-1.58]). Among hospital variables, a higher case-mix index, higher nurse staffing, and teaching status were associated with a lower hospital incidence of IHCA. <h3>Conclusions and Relevance</h3> This cohort study found that the incidence of IHCA varies markedly across hospitals, and hospitals with higher nurse staffing and teaching status had lower IHCA incidence rates. Future studies are needed to better understand processes of care at hospitals with exceptionally low IHCA incidence to identify best practices for cardiac arrest prevention.
Discussion of Diagnostic Excellence—Reply
Authors: Daniel Yang, Harvey V. Fineberg, Karen Cosby
Journal: JAMA (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
BOOK REVIEWS
Authors: N. JAVADPOUR
Journal: JNCI Journal of the National Cancer Institute (1990)

BOOK REVIEWS Get access Urologic Oncology . Herbert Lepor , Timothy L. Ratliff , eds. Dordrecht, The Netherlands : Kluwer Academic Publishers , 1989 , 243 pp. $95. NASSER JAVADPOUR NASSER JAVADPOUR Section of Urologic Oncology Department of Surgery University of Maryland School of Medicine22 S. Greene St. Baltimore, MD 21201 Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 82, Issue 5, 7 March 1990, Pages 426–427, https://doi.org/10.1093/jnci/82.5.426 Published: 07 March 1990
Osleriana
Journal: JAMA (1987)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
DESIDERATA IN BRITISH LIBRARIES
Journal: JAMA (2009)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
NT-02 * EARLY TREATMENT OF HER2-AMPLIFIED BRAIN TUMOURS WITH TARGETED NK-92 CELLS AND FOCUSED ULTRASOUND IMPROVES SURVIVAL
Authors: R. Alkins, A. Burgess, G. Francia, R. Kerbel, W. Wels, K. Hynynen
Journal: Neuro-Oncology (2014)

Malignant brain tumors have a dismal prognosis. Microscopic and often macroscopic residual remain after surgical resection, necessitating adjuvant chemo- and radiotherapy. Many intravenously delivered chemotherapeutic agents are hindered by the cerebral capillary endothelium and blood brain barrier (BBB), either due to their size, lipophilicity, or their interaction with efflux channels, resulting in modest treatment efficacy. Both those chemotherapeutic agents that cross the BBB and radiotherapy result in significant damage to healthy brain tissue. We previously demonstrated that targeted Natural Killer (NK-92) cells could be delivered to focal regions of the brain using a combination of focused ultrasound and Definity microbubbles. Targeted NK cells have advantages over other systemic therapies including their specific cytotoxicity to malignant cells, particularly those expressing the target antigen, in addition to sparing healthy cells and being unaffected by efflux channels. As such, once these cells gain access to the CNS, they can track to malignant tissues without inflicting collateral damage. We investigated whether multiple combined treatments of targeted NK-92 cells and focused ultrasound with microbubbles could slow tumor growth and improve survival in an orthotopic HER2-amplified rodent brain tumor model, using a human breast cancer line as a prototype. The HER2 receptor is expressed by a number of epithelial tumours including breast and glioblastoma. Breast cancers with HER2 amplification are more aggressive, have a higher risk of CNS metastasis, and poorer prognosis. We found that early intensive treatment with targeted NK-92 cells and ultrasound improved survival compared with bi-weekly treatments, or either treatment alone. The intensive treatment paradigm resulted in cure in 50% of subjects. Many tumour proteins could be exploited for targeted therapy with the NK-92 cell line, and combined with the mounting safety evidence for trans-cranial ultrasound, this may soon provide a non-invasive and highly targeted treatment option for patients with brain tumours.
Siglec-15: An Attractive Immunotherapy Target
Journal: Cancer Discovery (2019)

Siglec-15, which selectively drives immunosuppression in the tumor microenvironment, has emerged as a viable therapeutic target. In a phase I trial of NC318, a Siglec-15 antibody, encouraging efficacy was seen, including a complete response in non-small cell lung cancer refractory to PD-1 blockade.
Termination of pregnancy with reduced doses of mifepristone. World Health Organisation Task Force on Post-ovulatory Methods of Fertility Regulation.
Authors: F Look
Journal: BMJ (1993)

OBJECTIVES--To compare the abortifacient efficacy and side effects of three doses of the antiprogestin mifepristone plus prostaglandin for termination of early pregnancy. DESIGN--Randomised, double blind multicentre trial. SETTING--11 departments of obstetrics and gynaecology and of family planning, mostly in university hospitals, in seven countries. SUBJECTS--1182 women with an early pregnancy (menstrual delay of 7-28 days) requesting abortion. INTERVENTIONS--Single doses of 200 mg, 400 mg, or 600 mg mifepristone followed, 48 hours later, by vaginal pessary of 1 mg of the prostaglandin E1 analogue gemeprost. MAIN OUTCOME MEASURES--Outcome of treatment; duration and subjective amount of menstrual bleeding; side effects and complications; and concentrations of haemoglobin. RESULTS--Outcome was similar with the three doses of mifepristone. Of the 1151 women with known outcome, 95.5% had a complete abortion (364 (93.8%) of those given 200 mg mifepristone, 368 (94.1%) of those given 400 mg, and 367 (94.3%) of those given 600 mg), 3.7% had an incomplete abortion (14 (3.6%), 15 (3.8%), and 14 (3.6%)), 0.3% had a missed abortion (three (0.8%), one (0.3%), and none), and 0.4% had a continuing live pregnancy (two (0.5%), two (0.5%), and one (0.3%)). Of the 43 women who had incomplete abortion, 23 underwent emergency uterine curettage (usually for haemostatic purposes) and three of these women were given a blood transfusion. The numbers of reported complaints, bleeding patterns, and changes in blood pressure and haemoglobin concentrations were similar with the three treatments. CONCLUSIONS--For termination of early pregnancy a single dose of 200 mg mifepristone is as effective as the currently recommended dose of 600 mg when used in combination with a vaginal pessary of 1 mg gemeprost.
Ulcer Pathogenesis
Authors: T Alarcon, A Lowy, B Dworkin, K Van Horn, S Schwarz, E Lebovics, S Clark
Journal: Gut (1995)

Several phenotype and genotvpe methods have been used in trying to differentiate amongst re-infection or relapse after unsuccessful treatnent of H. pylori infection.Purpose: To determine if the Polimerase Chain Reaction with arbitrar primers, AP-PCR could be useful to differentiate H. pylori clinical isolates.Methods: 38 clinical isolates ofH.pylori obtained by standard methodology were studied: biopsies taken from digestive endoscopy were cultured in Microbiology Department and microorganisms identified by catalase, urease and oxidase positive tests. 18clinical isolates were from unrelated patients, the other 20 were separated into 10 groups: six with 2 isolates from different endoscopies of the same patient. 3with 2 isolates from the same endoscopy but with some morphology or susceptibility differences, the last group being 2 isolates from 2 brothers.DNA was extracted from a 48h H. pylori culture in blood agar plate by the CATB reagent method previously published.PCR was carried out in 25mcl containing 2Ong of H. pylori DNA, 3mM MgCI.. 20 pmoles of 10-nt primer (Akopyanz 1992), IU of Tub DNA polimerase (Amershan), 250mcM each dNTP in the polimerase buffer recommended by the manufacturer, under a drop of mineral oil.A HYBAID thermal cycler was used for amplification as follows: 4 cycles (94°C 5min.36C 5min, 72°C 5min), 30 cycles (94°C Imin; 36C Imin; 72°C 2min) and 72°C 10min.Results were detected in 2% agarose gel clectrophoresis.DNA from the same group were tested at the sane time.Results: fragments of amplified DNA from 1 to 12 bands for each isolate w.ere found.The results from the isolates of different endoscopies from the same patient were as follows: in 4 patients no difference was observed by this method between the 2 isolates, suggesting that the same strain was present, in the other 2 patients clinical isolate pre and post treatment were different according to the AP-PCR pattem.suggesting reinfection with a new strain.The clinical isolates obtained from the same endoscopy were identical and the 2 isolates obtained from 2 brothers were different, according to the AP-PCR pattem.Conclusion: In this study AP-PCR was a useful method to differentiate clinical isolates of H. pylori.
Erratum
Journal: BMJ (1905)

KUDIE"A& L *687 other children on thebeach, etc. M.O H. thereuponealled at the house, and dissuaded the mother against coDtinuing this practice.Next day the fatber asked M.O.H. to call upon him on the same subject, whiclh he did.During this interview P. entered the room (not the sick room) in which the father and M.O.H. were consulting, accused the latter of unprofessional conduct.and demanded to know what right he had to visit the housewithout first seeing him, P. P alsotold the parents tbere
Chest Diseases
Authors: William Lester
Journal: JAMA (1964)

This two-volume textbook contains an excellent compilation of current British thinking and experience. It represents the lineal descendant of a previous two-volume text, edited by Marshall and Perry, which had been for the past decade a standard text in pulmonary diseases. This present edition, edited by Perry and Sellors, can be recommended highly. In addition, the work is an excellent example of the beneficial effect of good editorial guidance in welding together many chapters written by more than 20 individual contributors. The fact that the new edition has ten more chapters and approximately 400 more pages than its predecessor indicates the rapid growth of knowledge in this field during the past ten years. The first volume, consisting of 31 chapters, is concerned primarily with general subjects relating to chest diseases, including succinct discussions of anatomy, physiology, radiology, anesthesia, and physiotherapy. The presentation continues with clinical disorders of the chest wall,
Power to the people
Authors: None The Lancet Digital Health
Journal: The Lancet Digital Health (2021)

Artificial intelligence (AI) for health is a rapidly evolving field, with many potential benefits and risks, but governing bodies are struggling to keep pace. This lag is further fuelled by a lack of comprehensive international guidance on how to ensure AI for health complies with ethical norms and human rights standards. To address this gap, WHO has published guidance on the ethics and governance of AI for health.
Clinical meaningfulness of a British Isles Lupus Assessment Group-based Composite Lupus Assessment response in terms of patient-reported outcomes in moderate to severe systemic lupus erythematosus: a post-hoc analysis of the phase 3 TULIP-1 and TULIP-2 trials of anifrolumab
Authors: Vibeke Strand, Sean O’Quinn, Richard A Furie, Eric F Morand, Kenneth C Kalunian, Erik G Schwetje, Gabriel Abreu, Raj Tummala
Journal: The Lancet Rheumatology (2022)